These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33312760)

  • 21. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
    Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
    Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
    Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
    Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
    Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
    Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
    Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
    Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
    Gnjatic S; Altorki NK; Tang DN; Tu SM; Kundra V; Ritter G; Old LJ; Logothetis CJ; Sharma P
    Clin Cancer Res; 2009 Mar; 15(6):2130-9. PubMed ID: 19276258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
    Diefenbach CS; Gnjatic S; Sabbatini P; Aghajanian C; Hensley ML; Spriggs DR; Iasonos A; Lee H; Dupont B; Pezzulli S; Jungbluth AA; Old LJ; Dupont J
    Clin Cancer Res; 2008 May; 14(9):2740-8. PubMed ID: 18451240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
    J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
    Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG
    Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
    J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
    Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
    J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response.
    Palmowski MJ; Lopes L; Ikeda Y; Salio M; Cerundolo V; Collins MK
    J Immunol; 2004 Feb; 172(3):1582-7. PubMed ID: 14734738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine.
    Albershardt TC; Parsons AJ; Reeves RS; Flynn PA; Campbell DJ; Ter Meulen J; Berglund P
    Vaccine; 2020 Apr; 38(17):3369-3377. PubMed ID: 32088020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
    Nicholaou T; Chen W; Davis ID; Jackson HM; Dimopoulos N; Barrow C; Browning J; Macgregor D; Williams D; Hopkins W; Maraskovsky E; Venhaus R; Pan L; Hoffman EW; Old LJ; Cebon J
    Cancer Immunol Immunother; 2011 Nov; 60(11):1625-37. PubMed ID: 21698545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
    Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J; Kluger H; Tejwani S; Green J; Ramakrishna V; Crocker A; Vitale L; Yellin M; Davis T; Keler T
    Sci Transl Med; 2014 Apr; 6(232):232ra51. PubMed ID: 24739759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.